PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24480403-7	2014	MMT provided a significant survival-advantage over surgical monotherapy for AC (P=0.004), SCC (P=0.01).	2-methylcyclopentadienyl manganese tricarbonyl	0-3	serpin family B member 3	Homo sapiens	90-93	
24480403-9	2014	MMT produced a pathologic complete response (pCR) in 25% and 31% of AC and SCC, respectively.	2-methylcyclopentadienyl manganese tricarbonyl	0-3	serpin family B member 3	Homo sapiens	75-78	
24480403-10	2014	Survival advantage accrued to MMT, pCR and node-negative patients: AC pCR versus surgical monotherapy (P=0.001); residual disease following MMT versus surgical monotherapy (P=0.008); SCC pCR versus surgical monotherapy (P=0.033).	2-methylcyclopentadienyl manganese tricarbonyl	30-33	serpin family B member 3	Homo sapiens	183-186